Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations
Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee B, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations. Annals Of Oncology 2008, 19: 1713-1719. PMID: 18515258, PMCID: PMC2735063, DOI: 10.1093/annonc/mdn352.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic AgentsBenzamidesBreast NeoplasmsBreast Neoplasms, MaleCarcinoma, Ductal, BreastFemaleHumansImatinib MesylateImmunologic FactorsMaleMiddle AgedNeoplasm MetastasisPiperazinesProspective StudiesProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrimidinesReceptor, Platelet-Derived Growth Factor betaConceptsMetastatic breast cancerPlatelet-derived growth factor receptorImatinib mesylateC-kitDisease progressionClinical activityB-fibroblast growth factorGrowth factorMedian overall survivalSerious adverse eventsPotential immunosuppressive effectsInterferon-gamma productionVascular endothelial growth factorAngiogenesis-related cytokinesEndothelial growth factorNovel molecular therapiesC-kit expressionGrowth factor receptorAdverse eventsObjective responseOverall survivalTreat analysisDismal prognosisMedian timeImmunomodulatory effects